HealthKick Podcast: Bionomic charges forward with lead drug candidate treatment for PTSD and social anxiety

Stockhead’s resident health and biotech expert Tim Boreham is putting down the microscope and picking up the microphone for another instalment of The Health Kick Podcast.

In this episode Tim chats to Dr Errol De Souza, executive chairman at Bionomics (ASX:BNO).

Bionomics is a global, clinical-stage biopharmaceutical company developing a pipeline of novel, ion channel targeting drug candidates designed to transform the lives of patients suffering from serious Central Nervous System (“CNS”) disorders.

Recent clinical studies have shown that Bionomics’ BNC210 has several properties which may be useful to treat PTSD, SAD and anxiety disorders. The drug has also received a US FDA Fast Track designation for both clinical indications.

To hear Tim and Errol discuss all this and more, click below!